EU Panel Validates Bristol Opdivo with Chemo for Non-Small Cell Lung Cancer

 If approved, the Opdivo regimen would be the first and only immunotherapy-based option authorized for use before surgery in patients with non-small cell lung cancer (NSCLC) in the European Union

Application based on CheckMate -816, the only Phase 3 trial to demonstrate improved event-free survival and pathologic complete response with an immunotherapy-based combination in the neoadjuvant setting of NSCLC

Opdivo-based treatments have shown clinical benefit in four Phase 3 trials in earlier stages of cancer

https://finance.yahoo.com/news/european-medicines-agency-validates-bristol-105900792.html